Casadio M, Lelli G, Giordani S, Boltri B, Blotta A, Busutti L, Ramini R, Falcone F, Pannuti F
Oncology Department St. Orsola-Malpighi Hospital, Bologna, Italy.
J Chemother. 1990 Jun;2(3):199-202. doi: 10.1080/1120009x.1990.11739018.
Forty-seven patients with advanced small-cell bronchogenic carcinoma (SCLC) were treated with a combination of epirubicin (4-EPIDX) (60 mg/m2 i.v.) and cisplatin (CDDP) (50 mg/m2 i.v.) on day 1, alternated with cyclophosphamide (CTX) (800 mg/m2 i.v.) day 1 and etoposide (VP16) (120 mg/m2 i.v.) on days 21-23. Four patients (9%) obtained a complete remission and 27 (57%) a partial remission with an overall remission rate of 66%. The median duration of response was 37 weeks (range 13-150) and the median duration of survival was 43 weeks (range 10-150). No severe bone marrow depression was noted. The other side-effects were of a mild grade.
47例晚期小细胞支气管癌（SCLC）患者接受了如下治疗方案：第1天给予表柔比星（4-EPIDX）（60 mg/m²静脉注射）和顺铂（CDDP）（50 mg/m²静脉注射）联合治疗，第1天给予环磷酰胺（CTX）（800 mg/m²静脉注射），第21 - 23天给予依托泊苷（VP16）（120 mg/m²静脉注射），两种方案交替进行。4例患者（9%）获得完全缓解，27例（57%）获得部分缓解，总缓解率为66%。缓解持续时间的中位数为37周（范围13 - 150周），生存持续时间的中位数为43周（范围10 - 150周）。未观察到严重的骨髓抑制。其他副作用为轻度。
